Less commonly prescribed antibiotic may be better

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

When Staphylococcus aureus bacteria gain access to a patient's bloodstream, the infection then becomes life threatening. Antibiotics can often cure this infection, but without any , more than 80% of patients with are likely to die. But what's the most appropriate antibiotic to use?

Kevin Chan, MD (Fresenius Medical Care North America and Massachusetts General Hospital) and his colleagues compared the effectiveness of various antibiotics at preventing hospitalization and death from bloodstream infection. They reviewed more than 500,000 blood culture results from their database, looking for methicillin-sensitive strains of S. aureus bloodstream infection. They also identified when physicians used or cefazolin to treat these infections. Vancomycin is often perceived as the better antibiotic because it has broad coverage against many strains of bacteria; however, other factors like the antibiotic's killing power and tissue penetration are also important factors in selecting the best treatment.

Among the major findings:

  • 56% of patients remained on vancomycin after blood culture results reported S. aureus bacteria were susceptible to cefazolin, while only 17% were treated with cefazolin.
  • Cefazolin-treated patients experienced a 38% lower rate of hospitalization and death compared with vancomycin-treated patients.
  • Cefazolin-treated patients also had a 48% lower rate of sepsis, which is the most serious form of bloodstream infection.
"I think the data suggest there is an opportunity to improve outcomes for patients through appropriate antibiotic selection," said Dr. Chan.

More information: The article, entitled "Prevalence and Outcomes of Antimicrobial Treatment for Staphylococcus Aureus Bloodstream Infection in Outpatients with End-Stage Renal Disease," will appear online on August 16, 2012, doi: 10.1681/ASN.2012010050

add to favorites email to friend print save as pdf

Related Stories

MRSA strain linked to high death rates

Nov 01, 2009

A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford ...

hVISA linked to high mortality: study

Sep 12, 2010

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

Vancomycin is the drug of choice for treating cellulitis

Oct 23, 2010

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, ...

Researchers closer to the super bug puzzle

Nov 11, 2011

Infectious diseases specialists from Austin Health are working closely with Microbiologists from the University of Melbourne to understand how Staph is becoming resistant to all antibiotic therapies.

Recommended for you

Liberia free of Ebola by Christmas, says president

9 hours ago

Liberia's president on Monday urged her countrymen to double their efforts to reach the government's goal of having zero new Ebola cases by Dec. 25, a target some experts have described as highly ambitious.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.